Update on ENESTop: TFR in CML after discontinuing nilotinib

Update on ENESTop: TFR in CML after discontinuing nilotinib

VJHemOnc

1 year
126 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular response. Here, Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an update on the exciting results of the trial and their implications. In particular, Prof. Hughes highlights how many patients who fail to maintain TFR can restart treatment and regain a deep response once more. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.
Up Next Autoplay
Treating CML & Myelofibrosis Patients
Treating CML & Myelofibrosis Patients
Category: Chronic Myelogenous Leukemia
317 Views
imedex 10 months
Resistance/intolerance to second generation TKIs in CML: what to do next?
Resistance/intolerance to second generation TKIs in CML: what to do next?
Category: Chronic Myelogenous Leukemia
153 Views
VJHemOnc 1 year
Benefits of second generation TKIs for CML in the frontline
Benefits of second generation TKIs for CML in the frontline
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Personalized therapy in leukemia: a case study
Personalized therapy in leukemia: a case study
Category: Chronic Myelogenous Leukemia
236 Views
VJHemOnc 1 year
New drugs for CML: are more to come?
New drugs for CML: are more to come?
Category: Chronic Myelogenous Leukemia
63 Views
VJHemOnc 1 year
Bosutinib: a new, safer TKI for frontline CML
Bosutinib: a new, safer TKI for frontline CML
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Asciminib has the potential to succeed where other TKIs have failed in CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Category: Chronic Myelogenous Leukemia
210 Views
VJHemOnc 1 year
DESTINY: achieving TFR by de-escalating therapy in CML
DESTINY: achieving TFR by de-escalating therapy in CML
Category: Chronic Myelogenous Leukemia
97 Views
VJHemOnc 1 year
Novel agents or imatinib for CML in the frontline setting?
Novel agents or imatinib for CML in the frontline setting?
Category: Chronic Myelogenous Leukemia
74 Views
VJHemOnc 1 year